Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep;42(3):629-652.
doi: 10.1007/s10555-023-10084-4. Epub 2023 Feb 2.

Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers

Yu Wang  1 , Baocheng Deng  2
Affiliations
Review

Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers

Yu Wang et al. Cancer Metastasis Rev. 2023 Sep.

Abstract

Hepatocellular carcinoma (HCC) is a common malignancy and one of the leading causes of cancer-related death. The biological process of HCC is complex, with multiple factors leading to the broken of the balance of inactivation and activation of tumor suppressor genes and oncogenes, the abnormal activation of molecular signaling pathways, the differentiation of HCC cells, and the regulation of angiogenesis. Due to the insidious onset of HCC, at the time of first diagnosis, less than 30% of HCC patients are candidates for radical treatment. Systematic antitumor therapy is the hope for the treatment of patients with middle-advanced HCC. Despite the emergence of new systemic therapies, survival rates for advanced HCC patients remain low. The complex pathogenesis of HCC has inspired researchers to explore a variety of biomolecular targeted therapeutics targeting specific targets. Correct understanding of the molecular mechanism of HCC occurrence is key to seeking effective targeted therapy. Research on biomarkers for HCC treatment is also advancing. Here, we explore the molecular mechanism that are associated with HCC development, summarize targeted therapies for HCC, and discuss potential biomarkers that may drive therapies.

Keywords: Biomarker; Hepatocellular carcinoma; Mechanism; Molecular target; Signaling pathway.

PubMed Disclaimer

References

    1. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660 - DOI - PubMed
    1. Jemal, A., Ward, E. M., Johnson, C. J., Cronin, K. A., Ma, J., Ryerson, B., et al. (2017). Annual report to the nation on the status of cancer, 1975–2014, Featuring Survival. JNCI: Journal of the National Cancer Institute, 109(9), https://doi.org/10.1093/jnci/djx030 .
    1. Villanueva, A. (2019). Hepatocellular Carcinoma. New England Journal of Medicine, 380(15), 1450–1462. https://doi.org/10.1056/NEJMra1713263 - DOI - PubMed
    1. In der Stroth, L., Tharehalli, U., Gunes, C., & Lechel, A. (2020). Telomeres and telomerase in the development of liver cancer. Cancers (Basel), 12(8), https://doi.org/10.3390/cancers12082048 .
    1. Delire, B., & Starkel, P. (2015). The Ras/MAPK pathway and hepatocarcinoma: Pathogenesis and therapeutic implications. European Journal of Clinical Investigation, 45(6), 609–623. https://doi.org/10.1111/eci.12441 - DOI - PubMed

Publication types

LinkOut - more resources